SCHEMBL5863997

SCHEMBL5863997

Cc1cc(Br)ccc1S(=O)(=O)N(Cc1ccc(O)cc1Cl)c1ccc(OCCN2CCCC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 2/20 0.44
MMP9 P14780 2/20 0.44
MMP13 P45452 2/20 0.44
ADAM17 P78536 2/20 0.44
ESR1 P03372 12/20 0.42
ESR2 Q92731 12/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ABCC1 P33527 1/20 0.40
LTA4H P09960 1/20 0.39
PTGS2 P35354 1/20 0.39
YES1 P07947 2/20 0.39
PDGFRB P09619 2/20 0.39
SRC P12931 2/20 0.39
CIT O14578 1/20 0.39
GAK O14976 1/20 0.39
EPHB6 O15197 1/20 0.39
RIPK2 O43353 1/20 0.39
PRKD3 O94806 1/20 0.39
ABL1 P00519 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5864192 0.92 ESR1 (0.42) MMP1MMP9MMP13ADAM17ESR1
SCHEMBL5863988 0.88 MMP1 (0.54) MMP1MMP9MMP13ADAM17ESR1
SCHEMBL5863613 0.87 ESR1 (0.41) MMP1MMP9MMP13ADAM17ESR1
SCHEMBL5863596 0.86 ESR1 (0.46) ESR1ESR2ABCC1LTA4HPTGS2
SCHEMBL5864264 0.85 MMP1 (0.48) MMP1MMP9MMP13ADAM17ESR1
SCHEMBL5863643 0.84 ESR1 (0.49) ESR1ESR2LTA4H
SCHEMBL5863908 0.84 ESR1 (0.48) ESR1ESR2ABCC1LTA4H
SCHEMBL5863788 0.84 ESR1 (0.44) ESR1ESR2ABCC1YES1PDGFRB
SCHEMBL5863977 0.84 ESR1 (0.44) ESR1ESR2ABCC1LTA4HPTGS2
SCHEMBL5864170 0.82 MMP1 (0.50) MMP1MMP9MMP13ADAM17ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053212-B2 Acyclic amide and sulfonamide ligands for the estrogen receptor PFIZER INC. (US) 2006-05-30 US claimed
EP-1542967-A1 AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR Pfizer Products Inc. (US) 2005-06-22 EP claimed
US-20040110767-A1 Acyclic amide and sulfonamide ligands for the estrogen receptor PFIZER INC 2004-06-10 US claimed
WO-2004026823-A1 AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR PFIZER PRODUCTS INC. (US) 2004-04-01 WO claimed
US-7053212-B2 Acyclic amide and sulfonamide ligands for the estrogen receptor PFIZER INC. (US) 2006-05-30 US disclosed
EP-1542967-A1 AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR Pfizer Products Inc. (US) 2005-06-22 EP disclosed
US-20040110767-A1 Acyclic amide and sulfonamide ligands for the estrogen receptor PFIZER INC 2004-06-10 US disclosed
WO-2004026823-A1 AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR PFIZER PRODUCTS INC. (US) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110767-A1 Acyclic amide and sulfonamide ligands for the estrogen receptor GHSR, GPER1, SSTR1 MMP1 1746/4885MMP9 2415/4885MMP13 2401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.